Carry out ophth exam before treatment & at least every 12 mth, but more frequently in treatment w/ daily dosage >6.5 mg/kg, renal insufficiency, visual acuity below 6/8, elderly >65 yr, cumulative dose >200 g. Discontinue if patient develops pigmentary abnormality, visual field defect or other abnormalities not explained by difficulty in accommodation. Concomitant use w/ tamoxifen is not recommended. Risk of hypoglycemia in patients treated w/ or w/o antidiabetics. Patients w/ congenital or documented acquired QT prolongation &/or known risk factors for prolongation of the QT interval eg, cardiac disease (eg, heart failure, MI), proarrhythmic conditions (eg, bradycardia <50 bpm), history of ventricular dysrhythmias, uncorrected hypokalemia &/or hypomagnesemia, during concomitant administration w/ QT interval prolonging agents. Discontinue if cardiac arrhythmia occurs during treatment. Cardiomyopathy resulting in cardiac failure. Patients taking medicines which may cause adverse ocular or skin reactions. Patients w/ hepatic or renal disease; severe GI, neurological, or blood disorders. Sensitivity to quinine, G6PD deficiency, porphyria cutanea tarda, psoriasis. Perform periodic blood counts & exam of skeletal muscle function & tendon reflexes in patients on long-term therapy. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Extrapyramidal disorders may occur. Not to be used in the treatment & prophylaxis, or prevention of relapse of malaria due to chloroquine-resistant strains of
P. falciparum & the exo-erythrocytic form of
P. vivax,
P. ovale &
P. malariae. Potential carcinogenic risk. Suicidal behavior has been reported (in very rare cases). May affect ability to drive & operate machinery. Pregnancy & lactation. Childn.
Sign Out
